Pregabalin Capsule
Product Images NDC 62135-444

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 62135-444). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Pregabalin Capsule 100mg 90s Bottle Label)

Pregabalin 100 mg capsules label from Chartwell Rx. The label indicates a prescription-only product with 90 capsules per container. It includes storage instructions, dosage and use directions, safety warnings to keep out of reach of children, and manufacturer details for CelltrionPharm Inc. and Chartwell RX LLC, along with the product NDC and barcode.*

FDA Label Image

Image Description (Pregabalin Capsule 150mg 90s Bottle Label)

Pregabalin Capsules 150 mg label from Chartwell RX, displaying a 90-capsule count. The label includes storage instructions, dosage and administration notes, and a barcode. Manufactured by CelltrionPharm, Inc. and marked Rx Only for prescription use.*

FDA Label Image

Image Description (Pregabalin Capsule 50mg 90s Bottle Label)

Pregabalin 50 mg capsules label from Chartwell Rx, LLC. The label indicates the product is prescription only (Rx) and contains 90 capsules. It provides storage instructions to keep at 25°C (77°F) with permitted excursions and notes the package is child-resistant. Manufacturer and barcode information are also visible.*

FDA Label Image

Image Description (Pregabalin Capsule 75mg 90s Bottle Label)

Pregabalin Capsules 75 mg oral capsules label from Chartwell RX, containing 90 capsules. The label includes storage instructions, dosage and usage information, manufacturer details (CeltrionPharm, Inc., Cheongju, S. Korea), and a barcode. The design features a red and blue color scheme with the labeler name, Chartwell Rx, prominently displayed.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Four lines represent Pregabalin at doses of 200 mg, 100 mg, 25 mg taken three times a day, and placebo. The graph visually compares the effectiveness of different Pregabalin doses against placebo in pain improvement across a range of improvement percentages.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 10)

A line graph comparing the percent of subjects improved over time from baseline to week 12, showing Pregabalin versus Placebo. The x-axis represents percent improved from baseline to week 12, and the y-axis shows the percent of subjects improved. The solid line indicates Pregabalin, and the dashed line indicates Placebo.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 11)

A line graph showing the percentage of subjects improved from baseline to Week 16 BOCF for Pregabalin versus Placebo. The x-axis represents percent improvement, ranging from greater than 0 to 100%, and the y-axis represents the percentage of subjects improved, ranging from 0 to 90%. Two lines are displayed: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin consistently showing higher improvement percentages across the range.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 12)

An illustration showing the formula for Creatinine Clearance (CLCr) calculation. The formula is based on age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 2)

A line chart comparing the percent of patients improved against percent improvement in pain from baseline. It shows two curves, one for Pregabalin 100 mg three times a day and one for placebo, indicating higher patient improvement with Pregabalin across the pain improvement spectrum.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 3)

A line graph showing the percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis for Pregabalin capsules at doses of 75 mg, 150 mg, and 300 mg taken twice daily, compared with placebo. The graph depicts that higher doses generally correspond to higher percentages of patients improved at various levels of pain improvement.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 4)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The chart compares the treatment effects on pain improvement.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 5)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows the trends of patient improvement across varying levels of pain relief percentages.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 6)

A bar chart presenting responder rates (%) from two clinical studies (Study E1 and Study E3) comparing placebo and various daily doses of Pregabalin (50 mg, 150 mg, 300 mg, 600 mg for E1; 600 mg and 900 mg for E3). The charts show increasing responder rates with higher Pregabalin doses versus placebo, with sample sizes indicated below each bar.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 7)

A dose-response curve chart displaying median percent seizure reduction from baseline on the vertical axis and dose in mg/day on the horizontal axis. It compares results from four studies (E1 BID, E2 TID, E3 BID, E3 TID) using different symbols to indicate the dosing regimens. Significant p-values (≤ 0.0001 or 0.0007) are annotated at various dose levels, showing dose-dependent efficacy compared to placebo.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 8)

A line graph showing the percent of patients improved relative to percent improvement in pain from baseline. It compares four groups: Pregabalin 600mg daily dose, Pregabalin 450mg daily dose, Pregabalin 300mg daily dose, and placebo. The y-axis is labeled 'Percent of Patients Improved,' and the x-axis is labeled 'Percent Improvement in Pain from Baseline.' Lines show trends for each dosage level and placebo.*

FDA Label Image

Image Description (Pregabalin Capsule Figure 9)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over time in days between Pregabalin and placebo groups. The chart shows two lines: a solid line for Pregabalin and a dashed line for placebo, illustrating differences in survival without LTR across a 180-day period.*

FDA Label Image

Image Description (Pregabalin Capsule Structure)

Chemical structure of the active ingredient Pregabalin, showing its molecular arrangement including amino and carboxylic acid functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.